We are focused on providing state-of-the art quantitative imaging and dosimetry for radiopharmaceutical therapies. These services are focused on addressing regulatory requirements, aiding in selection of patients mostly likely to respond, and helping reduce toxicities to normal organs.


Team

  George Sgouros, Interim CEO

George Sgouros, Interim CEO

  Eric Frey, CFO

Eric Frey, CFO

  Michael Ghaly, CTO

Michael Ghaly, CTO

  Omid Moghadam, COB

Omid Moghadam, COB